Ireland-based Perrigo Company plc (NYSE, TASE: PRGO) announced yesterday that it has named James Dillard as its new executive vice president and chief scientific officer.
In this new role, Dillard will be responsible for providing global oversight and coordination to Perrigo's Research & Development, Quality, Regulatory and Innovation efforts. He will report to president and chief executive officer, Murray S Kessler.
Dillard is joining Perrigo from Altria Group Inc, where he served as senior vice president, Research, Development and Sciences and chief innovation officer. He also led the manufacturing, science and technology functions for United States Smokeless Tobacco Company, part of the Altria organisation. Between 1987 and 2001, he worked for the FDA, where he last served as director of the Division of Cardiovascular and Respiratory Devices. During his 14 years at the FDA, he held various leadership roles in the Center for Devices and Radiological Health and the Office of Device Evaluation.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business